Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44335 clinical trials with a EudraCT protocol, of which 7366 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (10,988)
Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)

10,988 result(s) found. Displaying page 266 of 550.

EudraCT Number: 2011-003278-10

Sponsor Protocol Number: 192024-056

Start Date*: Information not available in EudraCT

Sponsor Name:Allergan Ltd.

Full Title: A Multicenter, Double-masked, Randomized, Active-controlled, Parallel Study of the Safety and Efficacy of Once-daily Bimatoprost Preservative-free Ophthalmic Solution Compared to Twice-daily Timolo...

Medical condition: Glaucoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.0	10015919 - Eye disorders	10018304	Glaucoma	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: FR (Ongoing) GB (Prematurely Ended) DE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2010-022939-11

Sponsor Protocol Number: PCYC-1104-CA

Start Date*: 2011-05-17

Sponsor Name:Pharmacyclics, Incorporated

Full Title: Multicenter phase 2 study of Bruton’s tyrosine kinase (Btk) inhibitor, PCI-32765, in relapsed or refractory mantle cell lymphoma

Medical condition: Relapsed or refractory mantle cell lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10026801	Mantle cell lymphoma refractory	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10026800	Mantle cell lymphoma recurrent	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) DE (Completed) AT (Completed)

Trial results: Removed from public view

EudraCT Number: 2010-024568-16

Sponsor Protocol Number: CV181-147

Start Date*: 2012-04-05

Sponsor Name:Bristol Myers Squibb International Corporation

Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in Pediatric Patie...

Medical condition: diabetes type 2

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10027433 - Metabolism and nutrition disorders	10067585	Type 2 diabetes mellitus	PT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: BE (Completed) Outside EU/EEA GB (Completed) IT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2010-022802-41

Sponsor Protocol Number: 3104001

Start Date*: 2011-02-25

Sponsor Name:Orion Corporation Orion Pharma

Full Title: SAFETY AND PHARMACOKINETICS OF ODM-201 IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER: OPEN, NON-RANDOMISED, UNCONTROLLED, MULTICENTRE, MULTIPLE DOSE ESCALATION STUDY WITH A RANDOMISED PHASE I...

Medical condition: Progressive castration resistant prostate cancer (MedDRA: hormone-refractory prostate cancer)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10062904	Hormone-refractory prostate cancer	LLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: GB (Completed) FI (Completed) CZ (Completed) EE (Completed)

Trial results: View results

EudraCT Number: 2012-000725-41

Sponsor Protocol Number: CLI-107-15

Start Date*: 2013-01-22

Sponsor Name:Cytheris S.A.

Full Title: A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy.

Medical condition: HIV-infected patients with Progressive Multifocal Leukoencephalopathy

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	15.0	10021881 - Infections and infestations	10036807	Progressive multifocal leukoencephalopathy	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2012-000537-39

Sponsor Protocol Number: M11-428

Start Date*: 2012-09-28

Sponsor Name:AbbVie Deutschland GmbH & Co. KG

Full Title: Long-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Com...

Medical condition: Alzheimer's disease

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.0	100000004852	10001896	Alzheimer's disease	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended)

Trial results: View results

EudraCT Number: 2011-005274-30

Sponsor Protocol Number: UCL_2011_DIDo

Start Date*: 2012-08-27

Sponsor Name:Université catholique de Louvain

Full Title: Efficacy and safety of a Double Icodextrin Dose in elderly incident CAPD patients on incremental Peritoneal Dialysis therapy: the DIDo study

Medical condition: Patients with chronic renal failure who are starting a Continuous Ambulatory Peritoneal Dialysis (CAPD) as first line dialyse.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.0	100000004865	10007184	CAPD	LLT

Population Age: Elderly

Gender: Male, Female

Trial protocol: BE (Completed) FR (Completed) GB (Completed)

Trial results: (No results available)

EudraCT Number: 2011-006293-72

Sponsor Protocol Number: GS-US-312-0117

Start Date*: 2012-05-08

Sponsor Name:Gilead Sciences, Inc.

Full Title: A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS 1101) for Previously Treated Chronic Lymphocytic Leukemia A C...

Medical condition: Chronic lymphocytic leukemia (CLL)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10008958	Chronic lymphocytic leukaemia	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) IT (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2011-004157-66

Sponsor Protocol Number: QRK202

Start Date*: 2012-05-29

Sponsor Name:Quark Pharmaceuticals, Inc.

Full Title: An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With A Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating The Efficacy and Safety...

Medical condition: Diabetic Macular Edema

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	100000004853	10057934	Diabetic macular edema	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) CZ (Completed) BE (Completed) GB (Completed)

Trial results: (No results available)

EudraCT Number: 2012-002968-27

Sponsor Protocol Number: CFTY720D2402

Start Date*: 2013-01-29

Sponsor Name:Novartis Farmaceutica, S.A

Full Title: A 48-week, double-blind, randomized, multi-center, parallelgroup study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with fing...

Medical condition: acute demyelinating optic neuritis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10029205 - Nervous system disorders	10030942	Optic neuritis	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) GB (Completed) DE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2012-003223-38

Sponsor Protocol Number: B3281004

Start Date*: 2013-05-14

Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017

Full Title: EXTENSION STUDY EVALUATING TREATMENT WITH PF-05280586 VERSUS RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE PARTICIPATED IN OTHER PF-05280586 CLINICAL TRIALS

Medical condition: RHEUMATOID ARTHRITIS

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	100000004859	10003268	Arthritis rheumatoid	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) ES (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2012-005624-15	Sponsor Protocol Number: CLJM716X2103	Start Date*: 2013-07-04
Sponsor Name:Novartis Farmacéutica S.A.
Full Title: A phase Ib/II, open-label study of LJM716 in combination with BYL719 compared to taxane or irinotecan in patients with previously treated esophageal squamous cell carcinoma
Medical condition: esophageal squamous cell carcinoma
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: ES (Completed) BE (Completed) GB (Prematurely Ended) FR (Prematurely Ended)
Trial results: View results

EudraCT Number: 2012-004491-18

Sponsor Protocol Number: BAY85-8501-16359

Start Date*: 2013-01-30

Sponsor Name:Bayer HealthCare AG

Full Title: A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY 85-8501 in Patients with non-Cystic Fibrosis B...

Medical condition: Non-Cystic Fibrosis Bronchiectasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	15.1	10038738 - Respiratory, thoracic and mediastinal disorders	10006445	Bronchiectasis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) ES (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2012-004423-20

Sponsor Protocol Number: V00498TA301

Start Date*: 2013-01-10

Sponsor Name:PIERRE FABRE MEDICAMENT

Full Title: STUDY OF EFFICACY AND SAFETY OF V0498 VERSUS PLACEBO IN ACUTE SORE THROAT PAIN

Medical condition: Acute sore throat

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10021881 - Infections and infestations	10049140	Pharyngotonsillitis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) GB (Completed) LV (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2011-005040-10

Sponsor Protocol Number: PRO045-CLIN-01

Start Date*: 2012-12-03

Sponsor Name:BioMarin Nederland B.V.

Full Title: A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple subcutaneous doses of PRO045 in subjects with Duchenne muscular dystrophy

Medical condition: Duchenne muscular dystrophy resulting from a mutation correctable by PRO045-induced DMD exon 45 skipping

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.1	10010331 - Congenital, familial and genetic disorders	10013801	Duchenne muscular dystrophy	PT

Population Age: Children, Adolescents, Under 18

Gender: Male

Trial protocol: BE (Completed) GB (Completed) IT (Prematurely Ended) FR (Prematurely Ended)

Trial results: View results

EudraCT Number: 2010-023589-39

Sponsor Protocol Number: ST10-01-302

Start Date*: 2012-04-10

Sponsor Name:Iron Therapeutics (Switzerland) AG

Full Title: A prospective, multicentre, randomised, double-blind, placebo controlled study with oral ST10-021 for the treatment of iron deficiency anaemia in subjects with quiescent Crohn's Disease where oral ...

Medical condition: Iron deficiency anaemia in quiescent Crohn's Disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	17.0	10005329 - Blood and lymphatic system disorders	10002062	Anaemia iron deficiency	LLT
	17.0	10005329 - Blood and lymphatic system disorders	10022972	Iron deficiency anaemia	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) AT (Completed) GB (Completed) HU (Completed)

Trial results: View results

EudraCT Number: 2011-001134-42

Sponsor Protocol Number: GS-US-291-0102

Start Date*: 2012-05-22

Sponsor Name:Gilead Sciences, Inc

Full Title: A phase 2, proof of concept, randomised, placebo-controlled, parallel group study to evaluate the effect of ranolazine and dronedarone when given alone and in combination on atrial fibrillation bur...

Medical condition: Paroxysmal Atrial Fibrillation

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.0	100000004849	10034039	Paroxysmal atrial fibrillation	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) GB (Completed) NL (Completed)

Trial results: View results

EudraCT Number: 2012-004373-80

Sponsor Protocol Number: ASBI603

Start Date*: 2013-06-21

Sponsor Name:Asubio Pharmaceuticals, Inc.

Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects with Acute Spinal Co...

Medical condition: Acute spinal cord injury

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	100000004852	10041545	Spinal cord and nerve root disorders traumatic	HLT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) CZ (Completed) ES (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2013-001473-24

Sponsor Protocol Number: F3Z-MC-IOQL

Start Date*: 2014-02-05

Sponsor Name:Eli Lilly and Company

Full Title: An Individualized treatMent aPproach for oldER patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus

Medical condition: Diabetes Mellitus, Type 2

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	100000004861	10063624	Type II diabetes mellitus inadequate control	LLT

Population Age: Elderly

Gender: Male, Female

Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2013-003997-28

Sponsor Protocol Number: GENA-15

Start Date*: 2014-01-15

Sponsor Name:Octapharma Pharmazeutika Produktions GmbH,

Full Title: Extension Study for Patients who completed GENA-05 (NuProtect) – to Investigate Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII

Medical condition: Severe Haemophilia A

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.1	100000004850	10018938	Haemophilia A (Factor VIII)	LLT

Population Age: Infants and toddlers, Children, Under 18

Gender: Male

Trial protocol: GB (Completed) DE (Prematurely Ended) FR (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Tue May 13 10:33:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA